Bedside testing of CYP2C19 gene for treatment of patients with PCI with antiplatelet therapy

Abstract Background To mitigate the risk of stent thrombosis, patients treated by percutaneous coronary intervention (PCI) are administered dual anti-platelet therapy comprising aspirin and a platelet P2Y12 receptor inhibitor. Clopidogrel is a prodrug requiring activation by the cytochrome P450 enzy...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Abdullah M. Al-Rubaish, Fahad A. Al-Muhanna, Abdullah M. Alshehri, Mohammed A. Al-Mansori, Rudaynah A. Alali, Rania M. Khalil, Khalid A. Al Faraidy, Cyril Cyrus, Mohammed M. Sulieman, Chittibabu Vatte, Daniel M. F. Claassens, Jurriën M. ten Berg, Folkert W. Asselbergs, Amein K. Al-Ali
Format: Artigo
Jezik:Inglês
Izdano: BMC 2020-06-01
Serija:BMC Cardiovascular Disorders
Teme:
Clopidogrel
Ticagrelor
Prasugrel
Platelet aggregation inhibitor
King Fahd hospital
Purinergic P2 receptor antagonists
Online pristup:http://link.springer.com/article/10.1186/s12872-020-01558-2
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items